BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$83.51 USD
-0.73 (-0.87%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $83.52 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth A Momentum D VGM
Brokerage Reports
0 items in cart
BioMarin Pharmaceutical Inc. [BMRN]
Reports for Purchase
Showing records 621 - 640 ( 816 total )
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES AND HEALTH CARE: The Week Ahead in Life Sciences - Upcoming Events for the Week of March 3
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
VIMIZIM Ready To Launch; Preliminary 2013 Results and 2014 Guidance Released; Reiterate NEUTRAL and $74 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Although VIMIZIM Approval Came Two Weeks Early, It Was Expected, In Our View; Reiterate NEUTRAL and Increasing 12-Month Price Target to $74 for Approval
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb. 17
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
February and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
February and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb. 3
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Corporate Update for Recent Announcements on Pipeline Progress; Reiterate NEUTRAL; Converting to 12-month Price Target of $72
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan. 20
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan. 20
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan. 13
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Previewing 4Q13 and 2014 Guidance
Provider: Nomura
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Initiating with Neutral Rating and $75 TP
Provider: Nomura
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Initiating on US Biotechnology Sector
Provider: Nomura